Pages that link to "Q27089118"
Jump to navigation
Jump to search
The following pages link to valbenazine (Q27089118):
Displayed 50 items.
- tardive dyskinesia (Q1546328) (← links)
- Solute carrier family 18 member A2 (Q2521094) (← links)
- NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study (Q34492934) (← links)
- Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder (Q38609330) (← links)
- Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine (Q38641750) (← links)
- Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? (Q38789841) (← links)
- Valbenazine for the treatment of tardive dyskinesia. (Q39170076) (← links)
- Valbenazine: First Global Approval (Q39348734) (← links)
- Valbenazine for Tardive Dyskinesia (Q39457348) (← links)
- Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects (Q41280807) (← links)
- Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder (Q41280820) (← links)
- Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder (Q41280845) (← links)
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia (Q45093763) (← links)
- The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. (Q45943181) (← links)
- Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites (Q46311357) (← links)
- Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective. (Q46429024) (← links)
- Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials (Q47346313) (← links)
- Ingrezza (Q47521714) (← links)
- Valbenazine for the treatment of tardive dyskinesia (Q47670227) (← links)
- Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review (Q47753620) (← links)
- Valbenazine granted breakthrough drug status for treating tardive dyskinesia (Q48088881) (← links)
- Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. (Q51010765) (← links)
- Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. (Q51762691) (← links)
- Valbenazine approved for treatment of tardive dyskinesia. (Q53782444) (← links)
- M16. Valbenazine (NBI-98854) for the Treatment of Tardive Dyskinesia: Analysis by Underlying Psychiatric Diagnosis in Phase III KINECT 3 Study. (Q54854373) (← links)
- SA17. Response to Treatment With Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia. (Q54918888) (← links)
- T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2. (Q55221457) (← links)
- Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia. (Q55415826) (← links)
- Overcoming barriers to effective management of tardive dyskinesia (Q64077422) (← links)
- 77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia (Q64113709) (← links)
- 67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder (Q64113714) (← links)
- 39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia (Q64113717) (← links)
- 38 Global Improvement and Patient Satisfaction: Results from a Long-term, Open-label, Rollover Study of Valbenazine in Tardive Dyskinesia (Q64113723) (← links)
- A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. (Q64882408) (← links)
- Valbenazine and Deutetrabenazine for Tardive Dyskinesia. (Q64882573) (← links)
- Ocrelizumab, edaravone, and valbenazine (Q88529561) (← links)
- Valbenazine for the treatment of tardive dyskinesia (Q89129630) (← links)
- Use of Valbenazine in a 54-Year-Old Female with Severe Tardive Dyskinesia (Q90094230) (← links)
- The effects of valbenazine on tardive dyskinesia in older and younger patients (Q90738511) (← links)
- The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder (Q90739887) (← links)
- Valbenazine and Trazodone overdose in a patient taking LAI and oral Paliperidone (Q90764060) (← links)
- A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia (Q91119337) (← links)
- Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? (Q91218928) (← links)
- Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study (Q91267338) (← links)
- Valbenazine in the treatment of tardive dyskinesia (Q91365068) (← links)
- Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia (Q92891173) (← links)
- Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia (Q92974468) (← links)
- 139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study (Q93210246) (← links)
- 140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses (Q93210364) (← links)
- 123 Long-Term Outcomes with Valbenazine 40 mg/day in Adults With Tardive Dyskinesia (Q93210502) (← links)